← All trials
NCT06590324
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Jul 30, 2025
- Completion date
- Nov 30, 2025
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Resverlogix CorpLead sponsor
- Resverlogix CorpOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.